


Claims:

1. Use of N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine of the formula I



(I)

or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of pulmonary hypertension.

2. The use according to claim 1, wherein the pulmonary hypertension is selected from primary pulmonary hypertension or secondary pulmonary hypertension.

3. The use according to claim 1 wherein a daily dose of 100 to 1000 mg of COMPOUND I of the formula I is administered to an adult human.

4. The use according to claim 3 wherein the daily dose is administered for a period exceeding three months.

5. The use according to any one of claims 1 to 4 wherein the pulmonary hypertension is not caused or accompanied by pulmonary fibrosis.


6. The use according to anyone of claims 1 or 4 wherein N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine of the formula I is in the form of a pharmaceutically acceptable acid addition salt.

7. The use according to claim 6 wherein N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine of the formula I is in the form of the monomethanesulfonate salt.

8. Use of a combination which comprises (a) N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine (designated hereinafter as COMPOUND I) and (b) at least one compound selected from the group comprising calcium channel antagonists, anticoagulants, endothelin receptor blockers, angiotensin-converting enzyme inhibitors, diuretics, and phosphodiesterase inhibitors for the manufacture of a medicament for the treatment of pulmonary hypertension.

9. Use of a combination according to claim 8 wherein (b) is at least one compound selected from the group comprising nifedipine, diltiazem, enalapril prostacyclin, adenosine, inhaled nitric oxide, warfarin, digoxin, bosentan, Viagra, and norepinephrine.

10. A method of treating humans suffering from pulmonary hypertension which comprises administering to a said human in need of such treatment a dose, effective against pulmonary hypertension, of N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine of the formula I



or a pharmaceutically acceptable salt thereof.